Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (CTOT-43)

NCT06280950 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT06280950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06280950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (CTOT-43)
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 2
Overall status
Recruiting
Start date
September 12, 2024
Completion date
June 30, 2030
Enrollment
340 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

liver transplant